Inovio’s DNA-Based Immunotherapy Lands Speedy FDA Nod for Rare Type of Tumor
Inovio’s Voceryq will compete with a Precigen product that last year became the first FDA-approved drug for recurrent respiratory papillomatosis, or RRP. While the two immunotherapies carry the same $460,000 list price, Inovio executives claim their product has another competitive advantage.
7 Potential Problems with Medicare’s AI Prior Authorization Experiment
The federal government is testing whether artificial intelligence can help Medicare identify unnecessary medical care, speed up the prior authorization process, and reduce healthcare spending. But a new report based on evidence recovered from a lawsuit raises concerns about the AI experiment.
Integris Health to Join Risant Health as Health System Dealmaking Stays Active
As health system dealmaking stays steady in 2026, Integris Health is joining Risant Health to accelerate value-based care. The partnership represents an integration of Risant Health's capabilities into Integris' existing system, rather than a traditional merger.
CMS Is Regulating the Wrong Thing — Here’s How to Fix Remote Patient Monitoring Without Losing the Care
Why should Medicare determine who is qualified to provide remote monitoring by asking who employs the nurse, rather than who is accountable for the patient's care?
How Innovation in BTK Inhibitor Development Is Improving Treatment Outcomes
BTK inhibitor has become an important treatment option for certain B-cell malignancies.